NuCana plc

Equities

NCNA

US67022C2052

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-29 pm EDT			5-day change	1st Jan Change
4 ^USD	0.00%		+0.25%	-45.91%

Apr. 26	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	MT
Apr. 25	European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	MT

NuCana plc Reports Earnings Results for the Full Year Ended December 31, 2023

March 20, 2024 at 04:31 pm EDT

NuCana plc reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was GBP 27.63 million compared to GBP 32.02 million a year ago. Basic loss per share from continuing operations was GBP 0.53 compared to GBP 0.61 a year ago.

Latest news about NuCana plc

European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	Apr. 26	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	Apr. 25	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 24	MT
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	Apr. 22	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	Apr. 19	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 17	MT
NuCana Completes ADS to Ordinary Share Ratio Change	Apr. 16	MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	Apr. 16	MT
ADRs Slump, VIA Optronics AG Declines 27%	Apr. 15	DJ
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Apr. 15	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	Apr. 04	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	Apr. 03	MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	Apr. 02	MT
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher	Apr. 01	MT
European Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday	Mar. 28	MT
Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	Mar. 28	MT
US Futures Little Changed Pre-Bell Thursday Ahead of Raft of Economic Data	Mar. 28	MT
NuCana Plans ADS Ratio Change to Comply With Nasdaq Rules; Shares Fall After Hours	Mar. 27	MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading	Mar. 27	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	Mar. 26	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	Mar. 25	MT
European Equities Traded in the US as American Depositary Receipts Slightly Higher in Friday Trading	Mar. 22	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Mar. 21	MT
NuCana plc Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
NuCana plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 20	CI

Chart NuCana plc

Duration

Period

More charts

Company Profile

NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3â-deoxyadenosine (3â-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Companyâs subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4 USD

Average target price

119.8 USD

Spread / Average Target

+2,895.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NUCANA PLC	-45.91%	8.38M
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	103B
REGENERON PHARMACEUTICALS, INC.	+1.62%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-16.67%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-13.21%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs